Competition authority interferes with Takeda's deal with Danish Orifarm

Following 'thorough investigations' the Danish Competition and Consumer Authority has approved that Orifarm can take over a range of drugs and factories from Japanese Takeda. However, in return, the firm has to divest several products and rights.
Orifarm CEO Erik Sandberg | Photo: Orifarm / PR
Orifarm CEO Erik Sandberg | Photo: Orifarm / PR
BY IBEN SCHMIDT, TRANSLATED BY NIELSINE NIELSEN

The Danish Competition and Consumer Authority could not approve the whole of Danish supplier company Orifarm's billion-kroner deal with Japanese medical company from last year.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading